Radcliffe Capital Management’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Radcliffe Capital Management’s Portfolio TLSIW Stock Details TLSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-138,194	Closed	-$6.67K	–	491
2023 Q2	$6.67K	Hold	138,194	–	–	﹤0.01%	469
2023 Q1	$11.1K	Hold	138,194	–	–	﹤0.01%	522
2022 Q4	$1.39M	Hold	138,194	–	–	0.04%	578
2022 Q3	$1.37M	Hold	138,194	–	–	0.03%	799
2022 Q2	$1.36M	Hold	138,194	–	–	0.03%	842
2022 Q1	$1.35M	Hold	138,194	–	–	0.03%	827
2021 Q4	$1.36M	Hold	138,194	–	–	0.04%	714
2021 Q3	$1.37M	Hold	138,194	–	–	0.04%	601
2021 Q2	$1.34M	Hold	138,194	–	–	0.04%	631
2021 Q1	$1.34M	Buy	+138,194	New	+$250K	0.05%	520

Other funds holding TLSIW

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.56% 1-Year Est. Return

MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Radcliffe Capital Management's TLSIW Position: Q3 2023 in Review

Radcliffe Capital Management sold out of TriSalus Life Sciences Warrant (TLSIW) in Q3 2023, closing a stake of 138,194 shares — an estimated $6.67K sold.

Radcliffe Capital Management first reported a position in TLSIW in Q1 2021 and held it in 10 quarters. The position peaked at $1.39M in Q4 2022. 19 funds tracked by Wall St. Rank hold TLSIW as of Q3 2023.

Radcliffe Capital Management reported no remaining TriSalus Life Sciences Warrant position as of Q3 2023 after selling out during the quarter.
Radcliffe Capital Management sold 138,194 TriSalus Life Sciences Warrant shares in Q3 2023, an estimated $6.67K.
Radcliffe Capital Management first reported a position in TriSalus Life Sciences Warrant in Q1 2021 and held it in 10 quarters.
Radcliffe Capital Management's TriSalus Life Sciences Warrant position peaked at $1.39M in Q4 2022.
19 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.